Unique ID,Start Date,End Date,Critical Count,Major Count,Minor Count,Not-Classified Count,Total Count Obs,HA Country,Health Authority,Brief Description,Protocol No,Inspection Type
377843,2024-06-20,2024-06-20,0,0,0,0,0,Taiwan,Taiwan - Food and Drug Administration,,17000139BLC3002,Clinical Investigator Inspection
377839,2024-06-12,2024-06-14,0,0,0,3,3,People’s Republic of China,People’s Republic of China - Jilin Medical Products Administration,,17000139BLC3002,Clinical Investigator Inspection
377840,2024-05-23,2024-05-25,0,0,0,7,7,People’s Republic of China,People’s Republic of China – Zhejiang Medical Products Administration,"2 sites completed on-site inspection during 23 to 25 May 2024, Site S59-CN10023/Dr. Hong Shen and site S59-CN10035 / Dr. Wen Li, two different department in the same hospital (The Second Affiliated Hospital of Zhejiang University School of Medicine). 1 Inspection report combined 2 sites' inspection findings. All of observation description and PI information have been recorded in report which cureve numer is 377840. The report of curver number 377844 have been cancelled.",17000139BLC3002,Clinical Investigator Inspection
377823,2024-05-03,2024-05-08,0,1,0,0,1,United States,United States - Food and Drug Administration,,17000139BLC3002,Clinical Investigator Inspection
377808,2024-04-22,2024-04-26,0,0,0,0,0,United States,United States - Food and Drug Administration,No 483 issued. Report closed. When and if the FDA Establishment Inspection Report (EIR) is received it will be attached to this Curve record.,17000139BLC3002,Clinical Investigator Inspection
